share_log

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target

Moomoo 24/7 ·  Mar 18 07:01

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment